Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
442.00    -4.00 (-0.90%)
Bid:
442.00
Ask:
446.50
Spread: 4.50 (1.018%)
Market Cap: £217.38m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Trading Update and Interim Management Statement

23 Oct 2013 07:00

RNS Number : 1453R
Zotefoams PLC
23 October 2013
 



23 October 2013

 

 

Zotefoams plc

("Zotefoams" or "the Company")

 

Trading Update and Interim Management Statement for the Quarter ended 30 September 2013

 

Zotefoams plc (the "Company"), a world leader in cellular material technology, today announces a trading update and its interim management statement for the third quarter ended 30 September 2013.

Growth in sales of High-Performance Products ("HPP") products and Azote® polyolefin foams in Asia in the third quarter has been offset by an unexpected shortfall in shipments to some European polyolefin customers, leaving total sales in the quarter at the same level as 2012 and below the level previously anticipated. These falls are, in the main, related to larger customers who are responding to continued destocking in the downstream market, which affects their demand levels in the short-term. The Board considers it prudent to assume that this trend will continue for the remainder of the year but, with the benefit of our shorter lead times, we expect to progress in this market in 2014.

Our HPP products business continues to grow strongly with long-term projects giving positive momentum into 2014 and beyond.

MuCell Extrusion, our technology licensing business, is focusing increasingly on consumer packaging. Given the scale of this opportunity further investment in our technology is being made during the fourth quarter.

Foreign currency rates have been less favourable in the third quarter compared to the first half of 2013 and the adverse impact in this period, mainly due to our US-dollar denominated investments, is in the region of £0.4 million.

The overall impact of these factors is that the Company expects second half profit to be below the level seen in the first half and therefore profit for the year to be below previous management expectations.

Although it is disappointing to see the current shortfall in European polyolefin foams, the Board considers the impact to be short-term and is encouraged by the performance of the business elsewhere. A return to growth is expected in 2014, and the Board remains confident in the long-term prospects for the business.

 

 

Enquiries:

Zotefoams plc

0208-664-1600

David Stirling, Managing Director

Clifford Hurst, Finance Director

FTI Consulting

0207-831-3113

John Dineen, Victoria Foster Mitchell

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular material technology. Using a unique manufacturing process with environmentally friendly nitrogen expansion, Zotefoams produces lightweight foams in Croydon, UK and Kentucky, USA for diverse markets worldwide through its global sales force. Zotefoams also owns and licenses patented MuCell® microcellular foam technology from a base in Massachusetts, USA to customers worldwide and sells T-Tubes® advanced insulation systems made from its patented ZOTEK® fluoropolymer foams.

 

www.zotefoams.com

 

ZOTEK®, Azote® and microZOTE® are registered trademarks of Zotefoams plc. MuCell® is a registered trademark of Trexel Inc. T-Tubes® is a registered trademark of UFP Technologies Inc.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCMTBRTMBBTBJJ
Date   Source Headline
5th Jun 20172:14 pmRNSDirector/PDMR Shareholding
1st Jun 20174:30 pmRNSDirector/PDMR Shareholding
31st May 20177:00 amRNSDirector/PDMR Shareholding
17th May 20177:00 amRNSTrading Update
12th May 201711:16 amRNSDirector/PDMR Shareholding
12th Apr 20173:34 pmRNSAnnual Report and Accounts and Notice of 2017 AGM
12th Apr 20173:24 pmRNSDirector/PDMR Shareholding
12th Apr 20171:55 pmRNSHolding(s) in Company
10th Apr 20174:02 pmRNSDirector/PDMR Shareholding
6th Apr 20172:27 pmRNSHolding(s) in Company
6th Apr 20172:25 pmRNSHolding(s) in Company
28th Mar 201711:36 amRNSDirector/PDMR Shareholding
27th Mar 201710:16 amRNSHolding(s) in Company
24th Mar 20173:33 pmRNSHolding(s) in Company
23rd Mar 201710:11 amRNSHolding(s) in Company
22nd Mar 20173:28 pmRNSHolding(s) in Company
14th Mar 20175:28 pmRNSDirector/PDMR Shareholding
14th Mar 20177:00 amRNSFinal Results
9th Mar 20177:00 amRNSCoveris using MuCell® technology
15th Feb 201710:46 amRNSDirector/PDMR Shareholding
10th Feb 20177:00 amRNSHolding(s) in Company
1st Feb 20176:27 pmRNSHolding(s) in Company
12th Jan 20179:36 amRNSDirector/PDMR Shareholding
11th Jan 201710:33 amRNSHolding(s) in Company
10th Jan 20175:34 pmRNSHolding(s) in Company
9th Jan 20177:00 amRNSTrading Update
6th Jan 20177:00 amRNSAppointment of Joint Broker
6th Jan 20177:00 amRNSAcquires full ownership of its joint venture
22nd Dec 20164:35 pmRNSPrice Monitoring Extension
13th Dec 20161:58 pmRNSDirector/PDMR Shareholding
24th Nov 20167:00 amRNSHolding(s) in Company
15th Nov 201612:40 pmRNSDirector/PDMR Shareholding
14th Nov 201610:30 amRNSDirector Declaration
28th Oct 20167:00 amRNSThird Quarter Trading Update
25th Oct 20164:40 pmRNSSecond Price Monitoring Extn
25th Oct 20164:35 pmRNSPrice Monitoring Extension
24th Oct 201612:07 pmRNSSecond Price Monitoring Extn
24th Oct 201612:02 pmRNSPrice Monitoring Extension
20th Oct 20164:40 pmRNSSecond Price Monitoring Extn
20th Oct 20164:35 pmRNSPrice Monitoring Extension
19th Oct 20163:43 pmRNSHolding(s) in Company
18th Oct 201611:56 amRNSDirector/PDMR Shareholding
14th Oct 20164:35 pmRNSPrice Monitoring Extension
13th Oct 20164:35 pmRNSPrice Monitoring Extension
12th Oct 20165:56 pmRNSDirector/PDMR Shareholding
5th Oct 20164:29 pmRNSHolding(s) in Company
14th Sep 201611:16 amRNSDirector/PDMR Shareholding
23rd Aug 20164:40 pmRNSSecond Price Monitoring Extn
23rd Aug 20164:35 pmRNSPrice Monitoring Extension
12th Aug 20167:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.